With Aduhelm slapped down by CMS, what's next for Biogen?

The Centers for Medicare & Medicaid Services (CMS) has maintained its restrictive stance on Aduhelm, limiting the Alzheimer’s disease drug’s coverage to randomized clinical trials. Now, it’s time for the drug’s developer, Biogen, to do some serious rethinking—including, as one analyst suggests, ceasing commercialization.